Twist Bioscience Corporation (TWST) Tops Q1 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Twist Bioscience Reports First Quarter 2022 Financial Results
February 4, 2022 7:30 AM EST-- Record Revenues of $42M; Increase of 49% over $28.2M in Fiscal 2021 --
-- Orders Increased 48% to $49.6M --
-- Increased Revenue Guidance for Fiscal 2022 --
SOUTH SAN FRANCISCO, Calif--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2022 ended December 31, 2021.
Weve started the year strong reporting record orders and revenue, with... More



